Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’ in Non-Small Cell Lung Cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

NANTES, France, July 28, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that Step-1 results of its Phase 3 clinical trial of investigational product...
July 28, 2020 10:38 ET | Source: ReportLinker

Europe Biopsy Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product, Technology, Application, and Country

New York, July 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Biopsy Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product,...
July 28, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea kündigt Präsentation von Daten auf dem ESMO Virtual Congress 2020 an

Basel, 28. Juli 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass drei Abstracts mit präklinischen und klinischen Daten zu ihrem FGFR-Kinase-Inhibitor Derazantinib und ihrem...
July 28, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea announces data presentations at ESMO Virtual Congress 2020

Basel, Switzerland, July 28, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR)...
July 27, 2020 08:30 ET | Source: Veru Inc.

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
July 27, 2020 08:01 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R/M Adenoid Cystic Carcinoma at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing...
July 27, 2020 07:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020

Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinomaOver 50% of enrollment target achieved; full enrollment expected around...
July 22, 2020 13:18 ET | Source: Oryzon Genomics, S.A.

ORYZON First Half Ended June 30, 2020 Results and Corporate Update

MADRID, Spain and CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
July 22, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of Two PV-10® Melanoma Cancer Abstracts at European Society for Medical Oncology (ESMO) Virtual Congress 2020

KNOXVILLE, TN, July 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from an ongoing clinical trial of investigational autolytic cancer immunotherapy PV-10...
July 09, 2020 18:43 ET | Source: MacroGenics, Inc.

MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...